Pelthos Therapeutics (PTHS)
Commercializes topical treatments for molluscum, impetigo, and head lice.
Something off on this page? Send us feedback.
Sells ZELSUVMI, an at-home topical treatment for molluscum contagiosum, while preparing XEPI for impetigo and XEGLYZE for head lice. Combines U.S. commercial operations with in-house active-ingredient manufacturing while licensing core NITRICIL intellectual property from Ligand.
Commercializes topical treatments for cutaneous infectious diseases, beginning with ZELSUVMI, an at-home nitric-oxide-releasing gel for molluscum contagiosum. XEPI for impetigo and XEGLYZE for head lice are FDA-approved acquired products in launch preparation, while CT2000 remains an early clinical program for eye pain.
Operates an in-house U.S. sales and market-access organization and manufactures ZELSUVMI's active ingredient in Durham; finished-drug production, logistics, and wholesale distribution rely on third parties. Revenue is currently tied to ZELSUVMI, with adoption dependent on physician and patient acceptance, pharmacy-benefit coverage, reimbursement, and sales-force execution. Core NITRICIL intellectual property is licensed from Ligand.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 14, 2026 | Oppenheimer | Reiterate | Outperform | $66 | $64 |
| Aug 13, 2026 | Industrial Alliance Securities | Target | $45 | ||
| May 15, 2026 | Oppenheimer | Target | $66 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $24.6M · Total debt $73.1M · Total assets $137.4M · Shareholders' equity −$1.5M
- Revenue
- $15.6M
- Operating income
- −$17.3M
- Net income
- −$23.4M
No dividends on record.
| Institutions17 holders · as of Mar 31, 2026 | 26.25% | 912.3K shares | |
| Otherremainder | 73.75% | 2.56M shares |
3.48M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Murchinson Ltd.Institution | 8.53% | 296,314 | 13Fas of Mar 31, 2026 |
Ikarian Capital, LLCInstitution | 7.38% | 256,598 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 2.68% | 93,093 | 13Fas of Mar 31, 2026 |
Boothbay Fund Management, LLCInstitution | 2.36% | 81,858 | 13Fas of Mar 31, 2026 |
J. Goldman & Co LPInstitution | 1.45% | 50,415 | 13Fas of Mar 31, 2026 |
| See all 18 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Verrica Pharmaceuticals
At-home molluscum treatment meets provider-applied YCANTH.
- Perrigo
OTC store-brand lice treatments pressure a future prescription launch.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pelthos Therapeutics | $25.91 | +3.56% | $87.0M | — | — | 2.0 | — |
| Verrica Pharmaceuticals | $5.42 | +3.44% | $92.6M | — | — | 3.1 | −53.9% |
| Perrigo | $14.05 | −2.97% | $2.00B | — | 6.1 | 0.5 | −3.2% |
| Median | — | 6.1 | 1.8 | −28.5% |